EFFECT OF BROMOCRIPTINE (CB-154) ON OESTROGEN-INDUCED PROLACTIN RELEASE
- 1 February 1979
- journal article
- research article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 90 (2), 193-197
- https://doi.org/10.1530/acta.0.0900193
Abstract
In order to study the interaction between estrogens and bromocriptine on PRL [prolactin] release, the ability of bromocriptine (CB-154) to counteract the estrogen-induced PRL release in 4 hyperprolactinemic amenorrhoeic women was evaluated. Bromocriptine acutely administered induced a similar percentage of PRL decrease in the same patient before and after estrogen administration. When bromocriptine was chronically administered, contemporary estrogen injection did not affect PRL release. Bromocriptine is able to block the release of PRL induced by estrogens, suggesting an interaction between estrogens and DA[dopamine]-mimetic compounds on PRL release.This publication has 4 references indexed in Scilit:
- INFLUENCE OF OESTROGEN ADMINISTRATION IN VIVO AND IN VITRO ON THE RELEASE AND SYNTHESIS OF PROLACTIN FROM INCUBATED PITUITARIESActa Endocrinologica, 1977
- DECREASE OF PROLACTIN BY METHYSERGIDE IN AMENORRHEIC HYPERPROLACTINEMIC WOMEN1,2Journal of Clinical Endocrinology & Metabolism, 1977
- Prolactin Secretion in vitro: Effects of Gonadal and Adrenal Cortical Steroids.Experimental Biology and Medicine, 1964
- Depletion of Prolactin-Inhibiting Activity of Rat Hypothalamus by Estradiol or Suckling Stimulus11Endocrinology, 1964